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While scientists were always cognizant of the fact that they must be objective about the ques-
tions they ask of nature, there was a time when they were less willing to consider the diverse 
views that could be contributed by female participation. Undervalued in terms of their intel-
lect, ambition, and curiosity, women found it difficult to compete for and/or retain a research 
post, particularly when they married. As a result, many women undaunted by existing con-
vention had to work without remuneration or were financially supported by colleagues and/
or relatives. But eventually, the time became right for a change in culture-bound attitudes. 
The present work revisits the inestimable accomplishments of five unique women in creating 
a positive environment for those scientists who have succeeded them.
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Prologue
Scientists, like everyone else, harbor a set of beliefs and values which in-
fluence their work. Because research scientists and physicians contributed 
significantly to patriarchal ideology and placed constraints on women in the 
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workplace during the first half of the twentieth century, women in science 
had to struggle against a patriarchal society that subjected them to a subordi-
nate position and rejection to achieve their respective goals. Discouragement 
was also enhanced by the advent of the National Socialists in Germany who 
promulgated a view of science that was antithetical to objectivity. It was du-
ring this era that any woman who wished to pursue a career in research was 
faced with formidable obstacles. Fortunately, a few extraordinary women 
produced cracks in what had been a male club of research scientists by virtue 
of their extraordinary talents as research scientists. 
Gerty Cori (1896-1957)
The first biographical sketch por-
trays the remarkable career of Gerty 
Cori (nee Radnitz), who became the 
first American woman to win the Nobel 
Prize in Physiology or Medicine despite 
several formidable obstacles encounte-
red during her career.1 Born in Prague 
in 1896 to an upper class Jewish family, 
Gerty received her early education at 
home. When her father was stricken 
with diabetes, he urged his daughter 
to become a physician in order to find 
a cure for the disease. However, it was 
her uncle, a Professor of Pediatrics at 
the University of Prague, who enco-
uraged her to attend medical school, 
a place where she identified only a few 
other female students. World War I in-
terrupted her education in 1916, while 
Gerty spent two years as an assistant at 
the medical school doing routine work. She eventually graduated from the 
medical school of the German University at Prague in 1920.
1 A portion of this biographical sketch is based on details of Gerty Cori’s life and career 
in: Larner J. Gerty Theresa Cori; Biogr. Mem Natl. Acad. Sci. 1992; 61: 111-135. See 
also Cohn, M. Gerty Theresa Cori” A Comprehensive Historical Encyclopedia; Jewish 
Women’s Archive; 1 March 2009. Whonamedit? Gerty Theresa Radnitz Cori. http://
www.whonamedit.com/doctor.cfm/2189.html. (retrieved October 22, 2014).
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Gerty, a woman of vitality and intelligence, became a constant compa-
nion of a fellow student, Carl Cori, during her first year of medical school 
in 1914. Gerty and Carl enjoyed outdoor activities and both had a strong in-
terest in laboratory research. Gerty married Carl following graduation and 
then converted to Catholicism to assuage her husband’s family, who feared 
that her Jewish background would jeopardize Carl’s medical career. They 
subsequently accepted positions in Vienna and decided to pursue careers 
in medical research, rather than in clinical practice. They began a life-long 
research collaboration, publishing their first joint paper as students in 1920, 
which was an immunological study of serum complement.2 This period 
encompassed troubled times in parts of Europe, including Austria, where 
economic depression and anti-Semitism were rampant. During 1921, Gerty 
worked as a member of the Pediatrics Department at Children’s Hospital in 
Vienna where she carried out research involving temperature regulation in 
myxedema and developed as a research scientist. Meanwhile, Carl moved to 
the University of Graz, Austria, where he fulfilled his clinical responsibilities 
by carrying out laboratory analysis in the mornings and conducting research 
in the afternoons. It was while working in the clinic that Carl, observing the 
anti-Semitic behavior of his superior, plus the uncompromising prejudice 
against woman scientists, concluded that the existing environment was not 
a suitable one for Gerty. However, because of food shortages that existed in 
Austria, Gerty developed Vitamin A deficiency which forced her to return 
home to Prague.3 
The political and economic upheaval that followed the defeat of the 
Austrians in World War I, as well as the lack of research funds, made career 
opportunities even more difficult. These factors prompted the Coris to seek 
opportunities outside of Europe. The Coris applied for positions overseas 
and even corresponded with the Dutch government to serve as doctors in 
Java (now Indonesia). Although Gerty was repeatedly warned that her conti-
nued collaboration with Carl might jeopardize his career, they were resolute 
in their desire to work together. In fact, Carl was offered faculty positions at 
2 Cori, K. und Radnitz G. Uber den gehalt des menschlichen an complement und nor-
mal amboceptor fur hammel blutkorperchen. Zeitschrift fur immunitatsforschung und 
Experimentelle Therapie. 1920: 29: 445.
3 American Chemical Society; National Chemical Landmarks. Carl and Gerty Cori 
and Carbohydrate Metabolism; 2004; pp. 1-16. Morrison, J. Mary Pickford: Pioneer of 
Endocrinology. In The Guardian; 27 August 2002. Silver, A. “Pickford (Lillian) Mary 
(1902-2002)”. Oxford Dictionary of National Biography; Oxford University Press. (Jan. 
2006). http://www.acs,org/content/acs/en/education/whatischemistry/landmarks/car-
bohydrate- metabolism,html (retrieved April 25, 2015). 
109
several prestigious universities, but those institutions refused to hire Gerty. 
Fortunately, an opportunity arose that was the stepping stone for their 
remarkable careers. In 1921, Dr. Harvey Gaylord, who was Director of the 
New York State Institute for the Study of Malignant Diseases (now Roswell 
Park Cancer Institute) in Buffalo, New York, was touring Europe to recru-
it a scientist. This trip was prompted by Gaylord’s astute realization that it 
was of prime importance to study cancer from a biochemical perspective. 
Furthermore, Gaylord was keenly aware that the best place to search for a 
top-notch biochemist was in Europe.4
Gaylord received excellent recommendations from European scientists 
about the young German-speaking Czech husband and wife team. As a 
result, in 1922 the Cori’s received an offer to move to Buffalo, where Carl 
assumed a position as biochemist at Roswell Park Cancer Institute (RPCI). 
Fortunately, Gaylord also saw fit to offer Gerty a position as an Assistant 
Pathologist, and she emigrated six months later. At first, Gerty was responsi-
ble for microscopic diagnostic service, while Carl’s duties focused on routine 
laboratory work for the hospital. The remainder of their time was spent on 
conducting research. Gerty and Carl readily adapted to their new environ-
ment and became naturalized citizens in 1928. Although they served on the 
staff of the first medical facility for dedicated cancer research and treatment 
in the United States, the Coris’ major interest was not in cancer but in de-
veloping an understanding of how cells derive energy from carbohydrates. 
They combined these interests in 1928 with their groundbreaking report on 
carbohydrate metabolism in tumor cells, which influenced future research 
on the regulation of normal and abnormal cells.5 Gerty continued to work 
in her husband’s laboratory despite warnings to confine her duties to those 
in the pathology laboratory. She temporarily circumvented this problem by 
using only a single microscope to study the effect of thyroxin on the multi-
plication rate of paramecium. However, a year after their arrival, objections 
to their collaboration waned and by 1928 Gerty had permanently settled in 
Carl’s laboratory as assistant biological chemist. 
In the 1920’s it was known that altered sugar metabolism could lead to 
diabetes and that insulin was able to counteract many effects of the dis-
ease. Since the underlying biochemical mechanisms involved with sugar 
4 Mirand, E. Legacy and History of Roswell Park Cancer Institute (1898-1998); 2004; The 
Donning Company Publishers; Virginia Beach, Virginia. pp. 175-177. Mirand, E. Better 
Together. Nobel Laureates Drs. Carl and Gerty Cori were partners in life and research. 
Roswell Park Alumni News; Alumni Spotlight. 2011; pp. 4-5.
5 Mirand, E. Legacy and History of Roswell Park Cancer Institute (1898-1998). 2004; p. 175
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regulation in the body were completely unknown, the Coris began their 
seminal investigations on carbohydrate metabolism. Their first joint report 
appeared in 1923, and during the next 12 years they produced more than 50 
publications, most of them coauthored with primary authorship going to 
which one of them had done the bulk of the work. However, Gerty Cori 
also published eleven articles as sole author. Much more significant than the 
number of publications is that the work uncovered fundamental biochemi-
cal knowledge that is still relevant to this day and which all first year medical 
students learn.
The research accomplished by the Coris while at RPCI encompassed 
three major areas of research: (1) how glucose is stored in the liver as glyco-
gen and metabolized when energy demands are high; (2) how this process is 
regulated by insulin and epinephrine; and (3) the identification and isolation 
of the enzymes involved in these processes. In 1929, the Coris proposed the 
theory that bears their names and later earned them a Nobel Prize. The dis-
covery of the “Cori Cycle”, which explains the utilization of energy by mus-
cle and liver, stemmed from their work addressing the question as to what 
regulates blood glucose concentrations. The Cori cycle not only offered in-
sight into how energy is utilized, but it also explained how hormones such as 
epinephrine influence the bioenergetics of this process by increasing the rate 
of conversion of glycogen to glucose, an effect reversed by insulin.6
Because RPCI was primarily an institution that focused on cancer re-
search, the Coris considered moving to an institution where the scope of 
their research could be expanded. Another factor in their decision may have 
been the relative lack of research funds available. Several institutions of-
fered Carl a position, but were unwilling to recruit Gerty. In 1931, a package 
deal was eventually provided that enabled the Coris to become equal part-
ners in the laboratory. Carl was offered a research position at Washington 
University in St. Louis, which gratuitously included Gerty. Her salary was 
10% of that offered to Carl. The gross disparity in salary existed even though, 
according to their son, Gerty was responsible for many of the original ideas. 
Nevertheless, the couple moved to St. Louis, where Carl became Chair of the 
Department of Pharmacology. University rules prohibited faculty appoint-
ments of two members of the same family, so Gerty was hired as a research 
fellow in Pharmacology. She worked for twelve years in this modest position 
6 The details of the research carried out by the Coris can also be found in their Nobel Lecture 
of December 11, 1946, entitled “Polysaccharide Phosphorylase”; Elsevier Publishing 
Company, Amsterdam 1964. See also Reference 3.
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until her husband was appointed Chair of the Biochemistry Department in 
the early 1940’s. Gerty was then appointed Associate Professor of Research 
Biological Chemistry and Pharmacology in 1943, and was promoted to the 
rank of Professor of Biological Chemistry in 1947.7
It was at Washington University where each area of research initiated 
in Buffalo reached fruition. The investigations were broadly based in that 
they encompassed experiments in vivo, in vitro and later on isolated enzymes. 
In 1936, the Coris identified a key new phosphorylated intermediate in car-
bohydrate metabolism, glucose-1-phosphate. Gerty discovered that when 
energy is required, glycogen is converted to glucose-1-phosphate in muscle 
by a reaction catalyzed by the enzyme phosphorylase. Because the reaction 
was shown to be reversible, glycogen synthesis was successfully carried out 
in vitro, representing the first demonstration of the biosynthesis of a macro-
molecule in a test tube.8 The success of these studies was a direct result of 
the development of precise analytical methods for the determination of glu-
cose, glycogen, lactic acid, and inorganic and organic phosphates. Not only 
did this discovery provide further insight into how the carbohydrate cycle 
utilizes energy, it became extremely useful for understanding and treating 
diabetes mellitus. In addition, Gerty had long been interested in glycogen 
storage diseases. Now she was able to define the nature of glycogen storage 
diseases in children; one involving excessive amounts of glycogen, the other 
abnormally branched glycogen.9 In 1947, the Coris were awarded the Nobel 
Prize “for their discovery of the course of the catalytic conversion of glyco-
gen”. Gerty Cori was not only the first American woman to be awarded the 
Nobel Prize in Physiology or Medicine, but the third woman world-wide; the 
previous recipients being Marie Curie and Irene Joliot-Curie.
Gerty Cori was the recipient of many other honors including: the Garvan 
Medal (1948), the St. Louis Award (1948), the Borden Award (1951) and an 
honorary Doctor of Science degree from Boston University (1948), Smith 
College (1949), Yale (1951), Columbia (1954) and Rochester (1955). In 1952, 
President Harry Truman named her to the National Science Board of the 
National Science Foundation. Gerty Cori was also honored by the release of 
a postage stamp in her name in 2008, which regrettably contained a printing 
error in the chemical formula of glucose-1-phosphate. In 2004, the American 
7 Gerty T. Cori Papers. Bernard Becker Memorial Library Archives. Washington 
University School of Medicine. http://beckerarchives.wustl.edu/=collections/
findingaid&id=8535&q=&rootcontenid=41.
8 Kornberg, A. Remembering Our Teachers. 2001 J. Biol. Chem. 276: 1-8.
9 Cori, G.T. 1953. Glycogen structure and enzyme deficiencies. Harvey Lectures 48: 145-171.
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Chemical Society designated the research of Gerty and Carl Cori as a 
National Historic Chemical Landmark.10 Her achievements are even more 
remarkable when it is realized that for many years she was marginalized in a 
non-tenure track research position at token salaries. Despite gender discrim-
ination and nepotism rules, she never stopped pursuing her life-long interest 
in research and published nearly 150 articles.11 
In addition to their accomplishments in research, Gerty and Carl Cori 
built a stimulating and vibrant working environment, which was considered 
one of the world’s most prestigious centers for biochemical research.12 The 
Coris’ prodigious skills in elucidating mechanisms involved in carbohy-
drate metabolism attracted the most distinguished biochemists to St. Louis, 
including six Nobel Laureates: Severo Ochoa, Earl Sutherland, Arthur 
Kornberg, Christian DeDuve, Edwin Krebs, and Luis Leloir. Kornberg, in 
particular, used Coris’ basic principles to discover the enzymatic mechanism 
of DNA synthesis. Later, he was integral in making discoveries which paved 
the way for gene cloning and much of molecular biology.
In 1947, while mountain climbing in Colorado, Gerty began to exhibit 
symptoms of a rare blood disease of the bone marrow called myelofibrosis.13 
However, despite severe pain, fatigue and multiple transfusions, she refused 
to curtail her laboratory activities and her work on the glycogen storage dis-
eases continued for another ten years. Her courage and determination en-
abled Gerty to demonstrate that the diverse forms of the disease were char-
acterized by a singular genetic error.14 Gerty Cori’s work in this area spawned 
a large number of studies on diseases of enzyme deficiency. But, this was to 
be her final contribution to science. On October 26, 1957, at the age of 61 she 
finally succumbed to renal failure. 
Gerty Cori was characterized as a person with a sharp mind and a passion 
for science. She always expressed a strong work ethic, optimism, and a broad 
perspective in the pursuit of scientific knowledge. Her commitment to her 
10 National Chemical Historical Landmark; Carl and Gerty Cori and Carbohydrate 
Metabolism. 2004. American Chemical Society. http://www,acs,org/content/acs/en/edu-
cation/whatischemistry/landmarks/carbohydratemetabolism’html.(accessed October 18, 
2014).
11 Gerty Theresa Cori. Women in Medicine at Washington University School of Medicine; 
Becker Memorial Library. (http://beckerexhibits.wustl.edu/women/cori.htm (accessed 
October 28, 2014).
12 See Reference 8.
13 National Chemical Historical Landmark, 2004. p. 7.
14 Cori, G.T., Biochemical Aspects of Glycogen Deposition Disease. 1958. Bibliotheca 
Paediatrica 14: 344-358.
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career can best be illustrated by the pronouncement that “the love for and 
the dedication to one’s work seem to me to be the basis for happiness”.15 In 
her view, her scientific contributions were the result of her European edu-
cation and the freedom and opportunities provided in the United States. 
As Arthur Kornberg noted in his tribute to the Coris, perhaps one could 
argue favorably that their monumental achievements deserve to be honored 
as much as the paladins of their era in politics, the military, and the arts.16
 Gertrude Elion (1905-1998)
The next biographical sketch por-
trays the remarkable career of Gertrude 
Elion, another Nobel Laureate who 
was willing to endure repeated disap-
pointments to ultimately achieve her 
life-long career goals to conduct bio-
chemical research. Because her entry 
into research was preceded by unchal-
lenging and non-paying jobs, the climb 
was steep; however, they did not deter 
Elion from accomplishing her ultimate 
objectives. The discrimination and dis-
appointment that she endured in her 
quest to become a successful scientist 
set an example for anyone who aspires to a more challenging career. 
Gertrude Elion was born in New York City; her father was a dentist and 
her mother a teacher.17 A precocious student, Elion at 15 decided to major in 
chemistry after her grandfather died of cancer. She took advantage of the 
free education provided by Hunter College in New York City at the time to 
obtain an A.B. degree in Chemistry. After graduating from college in 1937, 
Elion was unable to continue her education because of financial difficulties 
created by the Great Depression. But, Elion was determined to progress in 
her education and within a year she generated sufficient funds to obtain a 
15 Glories of the Human Mind by Gerty Cori. In Her Words. Women in the Health Sciences. 
Bernard Becker Medical Collection; Washington University School of Medicine. http:-
becker exhibits.wustl.edu/mowihsp/words/Cori/Essay.htm (retrieved May 1, 2015). 
16 See Reference 8.
17 Elion’s early personal life is described in: Autobiography of Gertrude B. Elion. The 
Oncologist 2006: 11: 966-968; and in Avery, M.E. Gertrude B. Elion; A Biographical 
Memoir. National Academy of Sciences 2000: 78: pp. 17-29. 
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Master’s Degree from New York University. Meanwhile, she also continued 
her quest to seek a more meaningful occupation. As a Chemistry major and a 
woman, she found it very difficult to find a job in science and so she took sev-
eral positions, including serving as a receptionist and teaching high school 
students and nurses. Elion was also hired to test food products for the A&P 
grocery store chain, which she found repetitive and unstimulating.
Prior to the golden age of pharmacology that existed in the United 
Kingdom during the 1930’s, pharmacology was considered a second tier 
biomedical science. The development of new drugs was a consequence of 
arduous trial-and-error and the element of chance, rather than rational de-
sign. The discovery of the sulfonamides as chemotherapeutic antimicrobial 
agents by Gerhard Domagk in 1935 was a direct consequence of screening a 
large number of diverse substances before sulfonamide containing dyes were 
synthesized by chemists at I.G. Farben in Germany. Prontosil was ultimately 
found to be the most effective of these dyes in protecting mice from a lethal 
dose of H. streptococci.18 Domagk’s development of sulfa drugs led Hitchings 
to believe that other substances that interfered with microbial metabolism 
could be employed as therapeutic agents.
In 1940, a biochemist named Donald Woods presented data favoring the 
possibility that sulfa drugs could arrest bacterial growth by acting as an anti-
metabolite. The hypothesis that other anti-bacterial agents acted in a similar 
manner was subsequently proposed by a colleague, Paul Fildes. Elion and 
Hitchings decided to incorporate the Woods-Fildes theory into a template 
facilitating the transition of anti-metabolites from the laboratory to the 
clinic.19 But, this would prove to be a prodigious task since only meagre bio-
chemical evidence was available to aid in interpreting any experimental re-
sults. Nevertheless, Hitchings made the critical insightful decision to target 
nucleic acids (DNA and RNA) and seek differences in the acid metabolism 
among normal, cancer, bacterial and viral cells. Extending research into this 
previously unexplored area appeared to be a rational way to develop drugs 
that could differentially block the growth of cancer cells and microorgan-
isms. This rationale would form the basis for developing new drugs against a 
variety of diseases and revolutionize the field of drug development.
18 Rubin, R.P. 2007: A Brief History of Great Discoveries in Pharmacology. Pharmacol. Rev. 
59: 315-318.
19 Lesch, J.E. The First Miracle Drugs. How the Sulfa Drugs Transformed Medicine; 2007; 
Oxford University Press, U.K., pp. 256-266.
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Viewing drug discovery from a rational perspective, rather than by tri-
al-and-error, Elion and Hitchings postulated that because normal cells rely 
upon the diet to replenish the body’s supply, folic acid synthesis might be 
preferentially inhibited to advantage in neoplastic and bacterial cells.20 The 
concept of differentially interfering with DNA biosynthesis would form the 
basis of understanding antimetabolites as antineoplastic and immunosup-
pressive agents. However, at the time, little was known about nucleic acid 
biosynthesis or the enzymes involved in this process. Although Elion was un-
familiar with purines or pyrimidines, she was given the task of investigating 
the purines, including adenine and guanine, which are two of DNA’s build-
ing blocks. After spending time in the library to uncover what was known 
about purine metabolism, Elion began testing whether any compounds 
were biologically active. She employed an assay system that Hitchings and 
Elvira Falco had developed. This assay employed Lactobacillus casei, which 
could grow in a mixture of thymine and purine, as well as synthesize pu-
rines, if provided with folic acid. In 1948, Elion discovered that bacterial cells 
required certain purines in order to make DNA.21 This finding led to the 
seminal hypothesis that if the incorporation of purines into bacterial cells 
could be interrupted by drugs, then the inhibition of nucleic acid synthesis 
and the suppression of bacterial growth might be expected as a consequence. 
This groundbreaking approach, if successful, would encourage new lines of 
experimentation and thereby develop new and more effective medications.
Elion then began to utilize her talents as a chemist by developing structur-
al analogues to block DNA production and thus interfere with cell growth. 
Using the L. casei assay system, Elion established that 2,6-diaminopurine 
inhibited bacterial growth which was specifically reversed by adenine. 
Although 2,6-diaminopurine proved pharmacologically active, it produced 
severe side effects which precluded its use in therapy. Undaunted by this set-
back, Elion went on to discover that the substitution of oxygen by sulfur at 
the 6-position of guanine and hypoxanthine produced effective inhibitors of 
purine metabolism. Two of these compounds, 6-mercaptopurine (6-MP) and 
20 Chemical Heritage Foundation. George Hitchings and Gertrude Elion. http://www.
chemheritage.org/discover/online-resources/chemistry-in-history/themes/pharmaceuti-
cals/restoring-and-regulating-the-bodys-biochemistry/hitchings--elion.aspx. Hall L.C. 
A life-saving team: Gertrude Elion and Dr. George Hitchings; North Carolina Museum of 
History; Office of Archives and History. 2007.
21 Koenig, R. The Legacy of Great Science: The Work of Nobel Laureate Gertrude Elion 
Lives On. The Oncologist (Milestones in Oncology) 2006: 961-965.
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6-thioguanine, displayed significant activity against a wide variety of tumors 
and leukemias when tested at the Sloan-Kettering Institute.22 
Gertrude Elion was only 32 years old when she synthesized 6-MP and 
6-thioguanine, two drugs that revolutionized the treatment of leukemia. As 
a consequence of her efforts, children stricken with this disease showed a re-
mission in their symptoms when 6-MP was used in combination with other 
drugs. The importance of this discovery is underscored by the fact that the 
Food and Drug Administration approved its use 10 months after the clini-
cal trials began and before all of the data defining its effectiveness became 
available.23 
Although Elion began taking courses as a doctoral student, she would 
be required to spend one full year as a student at Brooklyn Polytechnical 
Institute. However, recognizing her innate talents as a researcher, Hitchings 
argued that Elion would not need an advanced degree to carry out her inves-
tigations and advised her against continuing the matriculation. So, Gertrude 
Elion became one of the few Nobel Laureates who never obtained a doctor-
al degree.24 Even without an advanced degree, Elion was recognized for her 
accomplishments. She was elected to the prestigious National Academy of 
Sciences and awarded honorary degrees from several prestigious universities, 
including an honorary doctor of science degree from Harvard University. 
Because Elion achieved at the highest level, and her status as a first-rate sci-
entist was never in question, she never expressed any misgivings about not 
obtaining a Ph.D. degree.
In early 1970, a decision was made by Burroughs Wellcome to move to 
Research Triangle Park in North Carolina. Here research output did not di-
minish, but turned to the development of antiviral agents.25 Although, at the 
time, vaccination was the only approach to treating viral diseases, pioneer-
ing research projects involving antivirals were avoided because of the sup-
22 “Physiology or Medicine 1988- Press Release” Nobelprize.org. Nobel Media AB 2013. Web. 
23 May 2014. http//www.nobelprize.org/nobel_prizes/medicine/laureates/1988/press.
htm}; See also Koenig, R. The Legacy of Great Science: The Work of Nobel Laureate 
Gertrude Elion Lives on The Oncologist (Milestones in Oncology) 2006: 11: 961-965.
23 Turney, J. National drug design: Gertrude Elion and George Hitchings. Wellcome Trust. 
http://welcome.ac.uk/About-us/75th-anniversary/WTVM051718.htm (retrieved May 25, 
2015). Moran, L. Sandwalk: Strolling with a skeptical biochemist; pp. 1-12. http://sand-
walk.blogspot.com/2008/11/nobel-laureates-george-hichings-html (retrieved April 28, 
2015).
24 Autobiography of Gertrude G. Elion. The Nobel Prize in Physiology or Medicine. The 
Oncologist. 2006: 11: pg. 961-965. Avery, M.E. Biograph. Mem. 2000: 78: p. 21. 
25 Elion, G.B. The purine path to chemotherapy. Science 1989: 244: 41-48.
117
position that any compound capable of suppressing viral infections would 
be extremely toxic. Nevertheless, acyclovir, a drug synthesized by Howard 
Schaefer, was thoroughly investigated by Elion. She showed that this drug 
was not virucidal, but interfered with viral replication. Acyclovir is still the 
treatment of choice in several types of Herpes simplex and Varicella zoster 
infections.
In 1965, Elion attempted to improve the properties of 6-MP by using sul-
fur-substituted compounds.26 Her discovery of azathioprine, which replaced 
6-MP as an inhibitor of the immune response, enabled kidney transplanta-
tion to become a reality. Elion was also responsible for the introduction of 
allopurinol into the pharmacological armamentarium. Originally screened 
as a possible antineoplastic drug, allopurinol elicited an increase in the ef-
fectiveness of 6-MP by inhibiting its oxidative metabolism. Unfortunately, 
this drug produced a proportional increase in the toxicity of 6-MP. But, since 
xanthine oxidase catalyzes the conversion of hypoxanthine and xanthine to 
uric acid, as well as the oxidation of 6-MP, allopurinol proved to be an effec-
tive agent in the treatment of hyperuricemia (gout).26
Elion’s overwhelming success facilitated her gradual rise through the 
ranks until she became Head of the Department of Experimental Therapy in 
1967. At the time, Elion was probably the only woman to hold a top-
ranking position in a major pharmaceutical firm. Despite the fact that the 
Nobel Prize Committee rarely honors scientists who develop new drugs, in 
1988 Gertrude Elion and George Hitchings were awarded the Nobel Prize 
for designing new and effective therapeutic agents.27 The simple moral of the 
story of Gertrude Elion is that sufficient determination and commitment 
help greatly to clear the path to success. 
26 Elion, G.B. The purine path to chemotherapy. Science 1989.
27 Moran L A. 1988. Nobel Laureates: George Hitchings and Gertrude Elion. The Nobel 
Prize in Physiology or Medicine, In: Sandwalk: Strolling with a skeptical biochemist; pp. 
1-12. http://sandwalk.blogspot.com/2008/11/nobel-laureates-george-hichings-html (re-
trieved April 28, 2015).
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Marthe Vogt (1903-2003)
From the beginning of her life, 
Marthe Vogt was greatly influenced by 
a strong scientific environment. Born 
in Berlin, Vogt’s parents were well-
known neuroanatomists who associat-
ed with noted intellectuals of the time 
and welcomed educational endeavors 
and debate of issues. Early on, Vogt 
displayed a predilection for education-
al pursuits, becoming multilingual 
and ultimately graduating from Berlin 
University with both a medical degree 
and a doctorate in Chemistry. These 
accomplishments were an extreme 
rarity for women at the time. She sub-
sequently worked without pay at the 
Institute of Pharmacology in Berlin in the laboratory of Paul Trendelenburg, 
where she met another researcher who would achieve international fame, 
Edith Bulbring. Vogt’s prodigious talents did not go unnoticed. By the early 
1930’s, she became an established pharmacologist and by 1935 became head of 
the Chemical Division of the Kaiser Wilhelm Institute in Berlin.28
During the Nazi purge of the 1930’s, a wide range of attitudes towards 
the National Socialist government were expressed by non-Jewish scientists, 
ranging from fanatical following, blind obedience, muted indifference, and 
expressed opposition. Although not of Jewish heritage, Vogt was one of the 
few who was outspoken in her disdain for the Nazis. After reading Hitler’s 
biography Mein Kampf, she realized that scientific progress in her country 
would be suppressed by dogma, politics, and intolerance, and so she took a 
strong stand against her government. But it eventually became obvious to 
Vogt that she would have to leave Germany to continue her work.29
Respect for higher education had traditionally played a major role 
in German culture, and during the late 19th and early 20th centuries, the 
Germans had been the clear leaders of the scientific world. It was not until 
28 Greenfield, S. Marthe Louise Vogt FRS (1903-2003); In: Bindman, L. Brading A., and 
Tansey, T. Women Physiologists; London, Portland Press; 1993, p. 49-50.
29 Cuthbert, A.W. Marthe Louise Vogt. 8 September 1903-9 September 2003. Elected FRS 
1952. Biogr. Mem. Fell. R. Soc. 2003: 51: 412-413.
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the 1930’s with the advent of Adolf Hitler and the National Socialists that the 
United States and United Kingdom took its place when theoretical science 
became inexorably displaced by political issues. Jews were not alone in leav-
ing Germany. Many Aryan scientists departed because of political reasons 
or because they wished to pursue science unhindered by governmental influ-
ence. Marthe Vogt was one such individual.30 In 1935, she left Germany with 
a Rockefeller Travelling Fellowship that enabled her to work at the National 
Institute for Medical Research in London under the eminent Sir Henry Dale.
Like many expatriots, Vogt made her most important contributions in 
the UK in the area of neuropharmacology. Her work focused on the topogra-
phy of the brain and the role of catecholamines in animal behavior. Initially, 
she collaborated with Henry Dale, publishing a classical paper on the re-
lease of acetylcholine at the neuromuscular junction.31 The team of which 
Vogt was a key member proved conclusively that nerves arising from the 
spinal cord released acetylcholine causing skeletal muscles to contract. This 
groundbreaking work literally defined the physiological basis of movement. 
Vogt had the courage and tenacity to also undertake studies of the brain 
even though the techniques and instrumentation required were very rudi-
mentary. Together with Wilhelm Feldberg, Vogt provided presumptive evi-
dence that acetylcholine was a central neurotransmitter by measuring small 
amounts of choline acetyltransferase, the enzyme that catalyzes the synthe-
sis of the neurotransmitter.32 By helping to establish a role for acetylcholine 
in the central nervous system, Vogt’s work not only cemented her reputation 
as a leading pharmacologist, but also set the stage for the rational design of 
drugs to combat diseases such as Parkinson’s disease, schizophrenia, and 
depression. 
Not satisfied with her accomplishments in defining a central role for 
acetylcholine, in a paper published in 1949, Vogt collaborated with John 
Gaddum to devise a series of tests to distinguish various sympathomimet-
ic amines (particularly norepinephrine and epinephrine) in blood. 33 Her 
commitment to detail was exemplified in this study by establishing a set of 
eight bioassays which could be distinguished from one another by parallel 
30 Cuthbert A.W. Biogr. Mem. Fell. R. Soc. 2003.
31 Dale, H.H., Feldberg, W. and Vogt, M. Release of acetylcholine at voluntary nerve end-
ings. J. Physiol. 1936; 86: 353-380. 
32 Feldberg, W. & Vogt, M. Acetylcholine synthesis in different regions of the central ner-
vous system. J. Physiol. 1948: 107: 379-381.
33 Gaddum, J.H., Peart, W.S., & Vogt, M. The estimation of adrenaline and allied substances 
in blood. 1949: 108: 467-481.
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quantitative assays. Vogt eventually transferred to Cambridge University to 
work with another esteemed physiologist, E.B. Verney, and then with J.H. 
Gaddum in London. In 1947, she moved to Edinburgh as a lecturer and 5 
years later was elected a Fellow of the Royal Society, only the eighth women 
to be awarded that distinction.34
While in Edinburgh, Vogt also published a paper on the concentration of 
sympathin (adrenaline and noradrenaline) in the central nervous system.35 
Using fluorometric methods as well as bioassays, she found that the distribu-
tion of noradrenaline was not simply due to the presence of sympathetic va-
somotor nerves, but was unevenly distributed. Moreover the catecholamine 
content could be modified by drugs, thus reaffirming a functional role for 
sympathetic amines in the brain that was distinct from actions on vasomotor 
nerves. In being one of the first to demonstrate the release of multiple neu-
rotransmitters by the brain in vivo, Vogt also demonstrated their sensitivity 
to electrical stimulation and mode of anesthesia. This seminal work, which 
identified another neurotransmitter in the central nervous system, would 
spawn future studies and establish an international reputation for Vogt.
When World War II began, Vogt was still identified as an Enemy Alien 
Category A, even though she had begun the process of naturalization in 
1933. She was therefore vulnerable to immediate incarceration and was sum-
moned to appear in court. The judge ruled against her and she was taken to 
a police station for eventual imprisonment. But, on the way to the station a 
kindly policeman advised her to appeal. She was then given a brief period in 
which to find legal representation and garner support from prominent indi-
viduals who would speak on her behalf. When Verney and Feldberg learned 
of Vogt’s plight, they notified Henry Dale who went to the Home Secretary 
and had the matter resolved. Consistent with her persona, Vogt reportedly 
reprimanded those who had supported her for bothering the British govern-
ment at a time of war.36
In 1947, Vogt moved to Edinburgh where she first became Lecturer and 
then Reader in the Department of Pharmacology. Five years after her arriv-
al there, Marthe Vogt was elected to the Royal Society, a distinction that 
up to that time had been previously awarded to only eight other women. 
34 34 Wright P. 2003. Marthe Louise Vogt. The Lancet. 362: (9397) 1769-1770.
35 Vogt, M. 1954. The concentration of sympathin in different parts of the central nervous 
system under normal conditions and after the administration of drugs. J. Physiol. 123: 
451-481.
36 Marthe Vogt. In: The Telegraph. http://www.telegraph.co.uk/news/obituaries/1443084/
Marthe-Vogt.html
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In 1960, Marthe Vogt returned to Cambridge as Head of the Pharmacology 
Unit, Agricultural Research Council Unit of Animal Physiology; there she 
continued to maintain her scientific output. Recognizing that stress was a 
fundamental concept, Vogt studied multiple, rather than a single, neu-
rotransmitter.37 Vogt’s research interests included investigations not only on 
cholinergic systems, but also on central dopaminergic and serotonergic sys-
tems.38 Characterized as outspoken, principled, but compassionate, she was 
rigorous and precise in the pursuit of science and displayed an inordinate 
dedication to her work. Her research activity was characterized by cogent 
and creative ideas, detailed experimental analysis, and results that were al-
ways interpreted in a cautious manner. 
By the time Marthe Vogt retired in 1968, she had received innumerable in-
ternational honors for her work in neuropharmacology, including honorary 
membership in the American Academy of Sciences, British Pharmacological 
Society, Honorary D.Sc. and Honorary Member of the Physiological Society. 
In her personal life she found time to help refugees from Spain during the 
Spanish Civil War, assist displaced German Jews, and serve as a member of 
an anti-nuclear organization. In 1988, Vogt moved to La Jolla California to 
live with her sister, Marguerite, who was a noted cancer biologist. Marthe 
Vogt passed away in 2003, one day after her 100th birthday. She was not only 
a brilliant scientist, but a woman of indomitable spirit and vivacity. Her com-
mitment to the basic principles of science was unequaled.
37 Cuthbert, A.W. Biogr. Mems. Fell. R. Soc. 2005; pp. 415-420.
38 Banister, R.J., Portig, P.J. Sharman, D.F. and Vogt, M. Release by tubocurarine of dopa-
mine and homovanillic acid from the superfused caudate nucleus. J. Physiol. 1968; 194: 
565-572. Holman, R.B. and Vogt, M. Release of 5-hyroxytryptamine from caudate nucleus 
and septum. J. Physiol. 1972; 223; 234-254.
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Eleanor Zaimis (1915-1982)
The scientific exploits of the three 
women just chronicled should rank 
alongside those contributed by the pal-
adins of the golden age of physiology/ 
pharmacology that graced the United 
Kingdom and the United States well 
into the 20th century. However, there 
are also other women who should be 
cited because of their important con-
tributions to our knowledge of physi-
ology/pharmacology. One of these sci-
entists includes Eleanor (Nora) Zaimis, 
who in collaboration with William D. 
Paton, provided the first clear distinc-
tion between the nicotinic receptors at 
the neuromuscular junction of skeletal 
muscle and those on postganglionic autonomic nerves, thus setting the stage 
for the development of drugs for treating hypertension.
Born Eleanor Christides into a wealthy Greek family, Zaimis spent most 
of her childhood in Rumania.39 After graduating from Athens University 
in 1938, she was initially employed there in the pharmacology department 
where she taught medical students and conducted research on local anes-
thetics. She retained this position until 1947, and during this period that en-
compassed World War II she earned her medical degree with a thesis entitled 
Antagonism between local anesthetics and quinine.
Zaimis’s extracurricular activities defined her as a flamboyant and defi-
ant individual. As a member of the Greek national team for pistol shooting, 
she hid her pistols during World War II when the invading Nazis confiscat-
ed all weapons. During the war years, she was appointed Head of the youth 
centers in Athens. This experience made her cognizant of the health prob-
lems associated with poor sanitation and hygiene and prompted her to write 
a book on hygiene. From 1945-1947 she also served on a government com-
mittee to evaluate penicillin and streptomycin. In addition, realizing that 
knowledge about the chemical structure of pharmacological agents would 
39 A synopsis of Eleanor Zaimis’s early life and career can be found in: Dolphin, A. C. Eleanor 




be valuable for studies related to drug receptors, she obtained a B.Sc. degree 
in Chemistry in 1947.
Although married once in 1938, Zaimis married a second time in 1943 to 
John Zaimis, a naval officer and diplomat, and moved to England in 1947 as a 
British Council Scholar. Although she kept her married name and adopted 
British Nationality in 1954, Zaimis eventually separated from her husband 
several years later. After a brief period working as a research assistant at the 
University of Bristol in the Department of Pharmacology, Zaimis moved to 
the National Institute for Medical Research at Hampstead, where she served 
as lecturer and reader. It was in the Department of Chemistry and Physiology 
at The National Institute for Medical Research where Zaimis would earn ac-
claim by her collaboration with (Sir) William Paton, who was to become one 
of the most renowned pharmacologists of his time.40
Colleagues in the National Institute had been investigating the arrow 
poison and muscle relaxant curare prior to her arrival. But Paton and Zaimis 
decided to undertake a related study of the entire series of methonium com-
pounds with carbon chain lengths from C2 to C12. With her expertise in 
chemistry, Zaimis synthesized the remaining members of the chemical group 
to identify peak activity in C6 and C10. Their comprehensive studies demon-
strated that the longer chain methonium compounds (dexamethonium) pro-
duced neuromuscular blockade, while the shorter chain compounds (hexa-
methonium-C6) elicited blockade of autonomic ganglia. This work provided 
the first clear distinction between the nicotinic receptors of the neuromus-
cular junction of skeletal muscle and those on autonomic ganglia.41
 At first, Paton and Zaimis mainly regarded the methonium compounds 
as research tools. However, in a letter to Nature, they briefly suggested that 
“C6 (hexamethonium) offers the possibilities of clinical usefulness in such 
fields as hypertension and vascular disease”.42 They later explored the po-
tential clinical usefulness of the methonium compounds by heroically test-
ing the effects of one or another of these compounds on themselves! They 
also participated in a clinical study of the effects of hexamethonium and 
40 A synopsis of this work can be found in: Paton, W.D.M. and Zaimis, E.J. 1952. Pharmacol. 
Rev. The methonium compounds. 4: 219-253.
41 Paton, W.D.M. Zaimis, E.J. & Colquhoun D. (Commentary) (1997). The pharmacological 
actions of polymethylene bistrimethylammonium salts. Brit. J. Pharmacol. 120: 57-59. 
42 Paton, W.D.M. and Zaimis, E.J. 1948. Clinical potentialities of certain bisquaternary salts 
causing neuromuscular and ganglionic blockade. Nature 162: 810.
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pentamethonium on the blood pressure of humans.43 Prior to the 1950’s, the 
inadequate treatment for hypertension had been rest, sedation, and vene-
section. As a result of the work of Zaimis and Paton, hypertension became a 
treatable disease when hexamethonium became available. However because 
of its non-selective actions, ganglionic blocking agents such as hexamethoni-
um were soon preempted by more selective and less toxic anti-hypertensives. 
 After Zaimis moved to the School of Pharmacy at the University of 
London in 1948, she continued to work on ganglionic and neuromuscular 
blockade and explored various lines of research related to hypertension and 
migraine. In addition to the many papers Zaimis wrote, she and Paton co-
authored a monograph entitled Paralysis of Autonomic Ganglia by Methonium 
Salts in addition to the review published in Pharmacological Reviews.44
Eleanor Zaimis possessed a broad range of scientific interests regarding 
the sympathetic nervous system as exemplified by her serving as Editor of a 
volume on Nerve Growth Factor (NGF).45 Her interest in NGF stemmed from 
the fact that the adrenergic neuron in sympathetic ganglia was dependent 
upon the growth factor for normal development. Although it was discovered 
in the early 1950’s, the importance of NGF was viewed with significant skep-
ticism until its role in the development of the nervous system was elucidated. 
The volume edited by Eleanor Zaimis played a significant role in enhanc-
ing interest regarding the importance of NGF, which eventually earned the 
Nobel Prize for Rita Levi-Montalcini in 1986. 
In 1954, Zaimis was named Head of the Department of Pharmacology at 
the Royal Free Hospital School of Medicine, a medical school for women. 
For the next 25 years her research focused on analyzing drug interactions in 
the human body. Zaimis also continued her investigations of the sympathet-
ic nervous system and introduced the technique of immunosympathectomy, 
which Sir Henry Dale proclaimed “an important new chapter in develop-
mental physiology”.46 Because of her invaluable advice to pharmaceutical 
companies, Zaimis’s collaborations with industry also proved to be very 
43 Timmermann, C. 2008. In: Gaudilliere, J.P. Hexamethonium and the Treatment of High 
Blood Pressure, 1940’s-1950’s. 2008, The University of Manchester Library; pgs. 154-164. 
Hexamethonium and the Treatment of High Blood Pressure, 1940s-1950s. In: Therapeutic 
Agents between Plants, Shops, and Consulting Rooms. J.P. Gaudilliere and V. Hess (eds). 
2008, Max Planck Institute for the History of Science, Berlin; pp. 153-163.
44 Paton, W.D.M. & Zaimis. E.J. 1952. Pharmacol. Rev.4: 219-253. Paton, W.D.M. and Zaimis 
E.J. 1951. Paralysis of autonomic ganglia by methonium salts. Brit. J. Pharmacol. 6: 1-168.
45 Zaimis, E. (Editor). 1972. Nerve Growth Factor and its Antiserum; Athlone, London, 273 
pages. 
46 Paton, W.D.M. (1982) Obituary of Eleanor Zaimis. Brit. Med. J. 285: 1280.
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successful. Her studies on the chronic effects of low doses of drugs prompted 
her to warn clinicians that the deleterious side effects of drugs could nullify 
their beneficial actions.47
Recognition of her contributions was made when she became a member 
of the Royal College of Physicians in 1968 and a Fellow in 1974. In addition 
to these honors, Eleanor Zaimis also shared the Cameron Prize in 1956 and 
the Gairdner Foundation International Award in 1958 with Sir William 
Paton. Other accolades included becoming an honorary member of Rome 
Academy of Medicine, and being awarded the Cross of Commander of the 
Greek Order of Benevolence in 1962 and the Krakow Pharmacology Medal 
of the USSR Academy of Medical Sciences.48
Despite a heavy administrative load, Zaimis remained an active researcher 
and teacher until she neared retirement. However, she never forgot her roots 
and throughout her career she served as an advisor to the Greek government 
on university and pharmacological issues. In her later years she suffered from 
ill health and depression and retired to Athens in 1980. She passed away only 
two years after returning to her homeland. Although possessing a dominat-
ing personality, Zaimis was described as a generous person who contributed 
to the culture of both her native and adopted countries. But, perhaps even 
more importantly, Eleanor Zaimis played a major role in promoting the de-
velopment of new drugs that would possess a more favorable balance of ac-
tions in terms of selectivity and freedom of toxic side effects.
47 Zaimis, E.J. In: Cardiomyopathies. Drug induced myopathies. Ciba Foundation 
Symposium. 2009. pp. 213-223. 
48 Dolphin, A.C. In: Women Physiologists, 1993 pp. 131-133.
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Lillian Mary Pickford (1902-2002)
Mary Pickford was a pioneer in the 
emerging field of neuroendocrinolo-
gy by being a major participant in the 
development of the concept of neuro-
endocrine function in the neurohy-
pophysis (posterior pituitary) and the 
hypothalamus. Born in India, where 
her father was a successful business 
man, Pickford returned to England in 
1907 to be raised by her aunt and un-
cle. In 1925 she graduated from Bedford 
College having studied physiology, 
chemistry, and zoology. Encouraged 
by a family friend, Pickford decided on a career in medicine at an early age. 
Although the encouragement did not extend to the research laboratory, 
Pickford still decided to pursue a research career. However, because of the 
prejudicial attitudes harbored against women in science at the time, there 
existed a scarcity of jobs.49
Undaunted, Pickford found part-time work teaching the History of 
Science at University College, London, prior to becoming a research assis-
tant there. Moreover, her long term aspiration to study Medicine was sup-
ported by her godmother who left Pickford a small inheritance in her will. 
This inheritance, plus income from part-time teaching, enabled Pickford to 
continue her clinical studies at University College Hospital.50 She completed 
the program in 1933 and then took a position at Stafford General Infirmary as 
house physician. The position provided her with a variety of clinical expe-
riences, which included mending broken bones, treating victims of mining 
accidents, and delivering newborns.
Pickford began to become ambivalent about returning to laboratory re-
search.51 However, her career took a crucial turn in 1936 when she was in-
49 Silver, A. “Pickford (Lillian) Mary (1902-2002)). Oxford Dictionary of National Biography; 
Oxford University Press. (Jan. 2006). Retrieved 29 May 2015 (http://www.oxforddnb.
com/view/article/77182).
50 Silver, A. “Pickford (Lillian) Mary (1902-2002)”. Oxford Dictionary of National Biography; 
Oxford University Press. (Jan. 2006).
51 It was ironic that Pickford was encouraged by T.R. Elliott, Professor of Medicine at 
University College Hospital, to return to laboratory research, since many years ear-
lier Elliott had abandoned research to pursue clinical work after he had carried out 
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troduced to the eminent physiologist Ernest Starling by a family friend. She 
harassed Starling until he somewhat begrudgingly found her a part-time po-
sition with E.B. Verney, who had been appointed Chair of Pharmacology 
at University College London. Verney had previously collaborated with 
Starling to develop the heart-lung preparation and had demonstrated the 
importance of the pituitary gland in regulating urine flow. Pickford spent 
three productive years (1936-1939) with Verney, who fostered her life-long in-
terest in the mechanisms involved in antidiuretic hormone (ADH)-induced 
regulation of water balance by the pituitary gland. Her initial work on the 
synthesis and release of ADH and the control of urine flow would lead to 
experiments examining the effects of oxytocin on the reproductive system 
and vascular smooth muscle. She also explored the uterine and extra-uterine 
effects of estrogen, progesterone and a variety of vasoactive substances.52
In 1939, Pickford was offered a lectureship in Physiology at Edinburgh and 
because World War II had drastically reduced the number of academic staff, 
she was able to combine research with a heavy teaching load. During World 
War II, while on vacation leave in London, she helped overworked physi-
cians with their varied duties by patrolling air-raid shelters and providing 
medical assistance.53
After war ended, Pickford undertook her most significant work. Although 
the role of acetylcholine as a peripheral neurotransmitter had been estab-
lished by Otto Loewi and Sir Henry Dale and colleagues in the 1920’s and 
30’s, Pickford examined the possibility that acetylcholine could regulate 
urine flow by a central action. While acetylcholine was being accepted by 
the scientific community as a neurotransmitter in peripheral nerves, the idea 
that it could also play a similar role in the central nervous system seemed 
much less compelling to many of her colleagues. Pickford demonstrated by 
intravenous administration that acetylcholine elicited an anti-diuretic effect 
by inducing the release of ADH. Secretion of ADH was also observed by 
the injection of acetylcholine into the supra-optic nucleus of the brain of an 
anesthetized animal.54 Until the early 1950’s it was not known whether ADH 
experiments which elucidated the fundamental concept of neurochemical synaptic trans-
mission (Elliott, T.R. 1905; J. Physiol. 32: 401-467).
52 Phillips, M. Mary Pickford F.R.S. (1902-2002) In: Bindman, L, Brading, A. and Tansey T. 
Women Physiologists; 1993; pp. 41-42.
53 Professor Mary Pickford. The Telegraph. http:www.telegraph.co.ok/news/obituar-
ies/1405118/Professor-Mary-Pickford.html. (Retrieved 8 May, 2015). 
54 Pickford, M. and Watt, J.A. (1951). A comparison of the effect of intravenous and intraca-
rotid injections of acetylcholine in the dog. J. Physiol. 1951; 114: 333-335.
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and oxytocin, the hormone that stimulates uterine contraction during labor, 
were independent hormones. The results of her work with V.C. Abrahams 
provided evidence that ADH and oxytocin were separate substances.55 
The experiments performed by Pickford were technically very difficult, 
but her exquisite technique provided convincing experimental data. While 
not offering conclusive proof that acetylcholine was acting as a central neu-
rotransmitter, her findings provided strong support for the concept that ace-
tylcholine serves as a central as well as a peripheral neurotransmitter sub-
stance. In carrying out her experiments, Pickford always took exquisite care 
that the experimental dogs suffered minimal pain and stress. But she felt that 
the experiments conducted on live animals produced more meaningful re-
sults as they relate to physiology.56 
 Pickford was at the forefront in the development of the concept of neuro-
endocrine function in the posterior pituitary gland and the hypothalamus. 
One of her key contributions to physiology was that ADH was a key factor 
in regulating urine flow. However the broad scope of her views was exempli-
fied by her article in Pharmacological Reviews, in which she considered factors 
other than ADH that affect water regulation in the body.57 These factors in-
cluded hepatic disease and adrenal disorders that alter steroid balance. In 
addition, she noted that water excretion may also be diminished when blood 
pressure is reduced in the kidney or when renal vessels undergo vasocon-
striction. Finally, she was aware that such vascular changes could also be 
produced by alterations in the activity of the renal nerves. 
Because Pickford was a dedicated teacher, she was subsequently pro-
moted from Lecturer to Reader in 1952 and in 1966 became the first woman 
to be appointed to a medical Chair at Edinburgh University. This was the 
same year that she was elected Fellow of the Royal Society. Among her other 
distinctions, she was an honorary member of the Physiological Society and 
in 1935 became first female member of the Pharmacological Society, preced-
ing Edith Bulbring and Marthe Vogt. Her accomplishments as a pioneer of 
55 Abrahams, V.C. and Pickford, M. 1954. Simultaneous observations on the rate of urine 
flow and spontaneous uterine movements in the dog, and their relationship to posterior 
lobe activity. J. Physiol. 126: 329-346. Pickford, M. Stimuli that release hormones of the 
pars nervosa. In: Pioneers in Neuro-endocrinology (Meites, J. Donovan, B.T. & McCann, 
S.M. eds.) pp. 205-216; Plenum Press, New York.
56 Pickford, M. The action of acetylcholine in the supraoptic nucleus of the chloralosed dog. 
1947. J. Physiol. 106: 264-270. Phillips, M. Mary Pickford F.R.S. (1902-2002) In: Bindman, 
L, Brading, A. and Tansey T. Women Physiologists; 1993; pgs. 43-44.
57 Pickford, Mary. Antidiuretic Substances. Pharmacol. Rev. 1952: 4: 254-283.
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women in science clearly provide her with honored status in the pantheon of 
physiologists/pharmacologists of the 20th century.
Pickford remained at Edinburgh until she retired in 1972. However she 
continued to work 3 days a week as Special Professor of Endocrinology at 
the University of Nottingham, and in 1977 she spent 6 months as a Visiting 
Professor in Australia at the University of Brisbane. Mary Pickford authored 
over 60 papers and 13 book chapters and published a popular paperback The 
Central Role of Hormones in 1969.58 Pickford greatly enjoyed being mistaken 
for her namesake in the United States, who was a celebrated silent movie 
star. However, there is no doubt that Pickford ranked among the group of 
scientists who made their indelible mark during the 20th century. The ca-
reer of Mary Pickford a research scientist endured from the time she strug-
gled to find a suitable job to her appointment as Professor of Physiology at 
Edinburgh University. Thus it was not surprising that she would often ex-
press hostility regarding the attitude shown to women scientists during this 
period. But above all, her determination to overcome all obstacles enabled 
Pickford to achieve great success in her chosen career. Her legacy endures 
because of her unique contributions to our understanding of basic physio-
logical principles and to medical education. She died on the morning of her 
100th birthday (August 14: 2002).59
58 Pickford, M. D.Sc. F.R.S. The Central Role of Hormones. 1969. pp. 112; Oliver & Boyd; 
Edinburgh.
59 Morrison, J. Mary Pickford: Pioneer of Endocrinology. In The Guardian; 27 August 
2002. http://www.theguardian.com/news/2002/aug/27/guardianobituaries.obituaries 
(retrieved May 30 2015).
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Epilogue
This narrative, which is encapsulated in the biographies of five promi-
nent women scientists, hopefully provides perspective relative to the pursuit 
of science during an earlier time. There were many other women that I could 
have selected such as Rosalyn Yalow, Rita-Levi Montalcini, and Rosalind 
Franklin for example. But for the sake of brevity, I focused on certain women 
who helped to raise the discipline of Pharmacology, my own field of inter-
est, to a level comparable to other basic biomedical sciences. Edith Bulbring, 
an elite member of this group, was also not included because so much has 
been written about her by a former colleague Alison Brading that anything I 
might add would just be superfluous.
The long and fruitful years in research enjoyed by the women portrayed 
in this work helped to set the tone for the marked change in the culture of 
scientific research as we know it today. Although the early success of women 
in science may be attributed to determination, thoroughness, an open mind, 
and sheer intellect, success was also achieved by those who had the foresight 
or tenacity to overlook or circumvent difficulty when encountered. Other po-
tential factors which led to the development of an elite population of women 
scientists include: genetics, family values, and serendipity. In addition, the 
assistance of scientific stalwarts such as Sir Henry Dale, John Gaddum, E.B. 
Verney, and J.H. Burn as mentors helped to mitigate some of the challenges 
that these women endured. Their successes were also of major significance 
because of the encouragement they gave to other women engaged in scien-
tific endeavors. Finally, it is my sincere hope that this historical account will 
serve to reaffirm and celebrate the traditions of excellence that the careers of 
these redoubtable scientists surely convey.
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Sažetak
Dok su znanstvenici oduvijek bili upoznati s činjenicom da moraju biti objektivni vezano uz 
pitanja koja postavljaju o prirodi, u neka su vremena manje uzimali u obzir različite poglede 
žena. Podcjenjivanima u smislu svoje inteligencije, ambicije i radoznalosti, ženama je bilo 
teško natjecati se za radno mjesto istraživačice i/ili ga zadržati, posebice nakon udaje. Kao 
rezultat mnoge su žene, ne obazirući se na postojeće običaje, radile bez naknade ili su ih 
financijski pomagali kolege i/ili rodbina. Konačno, došlo je vrijeme za promjene u kulturo-
loškim stavovima. Ovaj rad preispituje neprocjenjiva dostignuća petero jedinstvenih žena u 
stvaranju pozitivnog okruženja za znanstvenice nakon njih.
Ključne riječi: biologinje; Gerty Cori; Gertrude Elion; Marthe Vogt; Mary Pickford; Elinor 
Zaimis.
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